// App-Quantinova.ai

SAT0127 : CHILD OUTCOME AFTER CERTOLIZUMAB PEGOL EXPOSURE IN RHEUMATOID ARTHRITIS PREGNANCIES: A CASE SERIES REPORT

Researchers

Presenter

  • M. Meroni

Principal Investigators

  • V.L. Ramoni

  • A.L. Brucato

  • M. Limonta

  • M. Ostensen

  • M. Cutolo

Medical Centers

  • Rheumatology Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy

  • Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, St. Olavs Hospital, Trondheim, Norway

  • Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy

Locations

  • Italy

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Congenital disorder

Disease

  • Rheumatoid arthritis

  • Congenital hemidysplasia with ichthyosiform erythroderma and limb defects

Biomarkers

  • Cartilage oligomeric matrix protein

  • Tumor necrosis factor

Drug/Treatment

  • Certolizumab pegol

  • Hydroxychloroquine

  • amphotericin b cholesteryl sulfate complex Intravenous

  • Sulfasalazine

  • amphotericin

  • Methotrexate

  • Infliximab

  • Etanercept

  • CHS-0214

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved